Aiden Flynn

Chief Executive Officer, Exploristics

Aiden Flynn is the founder and CEO of Exploristics and has 25 years’ experience as a statistician in drug discovery and clinical development.

After seven years as a Lecturer at University College London, Aiden spent ten years at GlaxoSmithKline as a Director of Statistical Support for Biomarker Studies across research and development before founding Exploristics in 2009. At Exploristics, Aiden has created an innovative and profitable company and overseen its ongoing growth and transition from a specialist statistics consultancy to a provider of innovative specialist software with wrap-around biostatistics support. As such, Exploristics caters to a wide range of global healthcare developers from the world’s top pharmaceutical companies to biotechnology, medical device and diagnostic start-ups.

With key expertise in emerging approaches to clinical development such as Precision Medicine and biomarker discovery, validation and integration, Aiden has worked closely with regulatory authorities, such as the FDA and EMA, to develop tools and guidelines that support the use of biomarkers in clinical studies. He has over 40 publications in peer reviewed journals and books and is an invited speaker at international conferences. Aiden is also a member of the Precision Medicine Advisory Board at Merck Biopharm and is involved in the Precision Medicine Steering Group, offering strategic advice to the Department of Health

Leonardo Royal Hotel London Tower Bridge

16 May 2023